SCM
CTSO icon

Soleus Capital Management’s Cytosorbents Corp CTSO Stock Holding History

Soleus Capital Management’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-800,000
Closed -$6.5M – 77
2021
Q3 		$6.5M Buy
+800,000
New +$6.5M 1.01% 30
2020
Q2 		– Sell
-69,600
Closed -$538K – 64
2020
Q1 		$538K Buy
+69,600
New +$351K 0.63% 33

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Soleus Capital Management's CTSO Position: Q4 2021 in Review

Soleus Capital Management sold out of Cytosorbents Corp (CTSO) in Q4 2021, closing a stake of 800,000 shares — an estimated $6.5M sold.

Soleus Capital Management first reported a position in CTSO in Q1 2020 and held it in 2 quarters. The position peaked at $6.5M in Q3 2021. 91 funds tracked by Wall St. Rank hold CTSO as of Q4 2021.

  • Soleus Capital Management reported no remaining Cytosorbents Corp position as of Q4 2021 after selling out during the quarter.
  • Soleus Capital Management sold 800,000 Cytosorbents Corp shares in Q4 2021, an estimated $6.5M.
  • Soleus Capital Management first reported a position in Cytosorbents Corp in Q1 2020 and held it in 2 quarters.
  • Soleus Capital Management's Cytosorbents Corp position peaked at $6.5M in Q3 2021.
  • 91 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2021.

Based on Soleus Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.